Does myocardial injection of human mesenchymal cell-derived EVs improve myocardial function and increase angiogenesis in a swine model of chronic ischemia?
Human mesenchymal cell-derived extracellular vesicles improve blood flow and cardiac function in a swine model of chronic ischemia by promoting angiogenesis.
In the setting of chronic myocardial ischemia, myocardial injection of human mesenchymal cell-derived EVs increases blood flow to ischemic myocardial tissue by induction of capillary and arteriolar growth via activation of the protein kinase B/endothelial nitric oxide synthase and mitogen-activated protein kinase signaling pathways resulting in increased cardiac output and stroke volume.
Potz et al. (Tue,) studied this question.